<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38287294</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7525</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Health and quality of life outcomes</Title><ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation></Journal><ArticleTitle>Health-related quality of life in mild-to-moderate COVID-19 in the UK: a cross-sectional study from pre- to post-infection.</ArticleTitle><Pagination><StartPage>12</StartPage><MedlinePgn>12</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12955-024-02230-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to estimate the impact of mild-to-moderate COVID-19 on health-related quality of life (HRQoL) over time among individuals in the United Kingdom, adding to the evidence base that had focussed on severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A bespoke online survey was administered to individuals who self-reported a positive COVID-19 test. An amended version of a validated generic HRQoL instrument (EQ-5D-5L) was used to measure HRQoL retrospectively at different timepoints over the course of an infection: pre-COVID-19, acute COVID-19, and long COVID. In addition, HRQoL post-COVID-19 was captured by the original EQ-5D-5L questionnaire. A mixed-effects model was used to estimate changes in HRQoL over time, adjusted for a range of variables correlated with HRQoL.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study recruited 406 participants: (i) 300 adults and 53 adolescents with mild-to-moderate COVID-19 who had not been hospitalised for COVID-19 during acute COVID-19, and (ii) 53 adults who had been hospitalised for COVID-19 in the acute phase and who had been recruited for validation purposes. Data were collected between January and April 2022. Among participants included in the base-case analysis, EQ-5D-5L utility scores were lower during both acute COVID-19 (&#x3b2;=-0.080, p&#x2009;=&#x2009;0.001) and long COVID (&#x3b2;=-0.072, p&#x2009;&lt;&#x2009;0.001) compared to pre COVID-19. In addition, EQ-5D-5L utility scores post-COVID-19 were found to be similar to the EQ-5D-5L utility scores before COVID-19, including for patients who had been hospitalised for COVID-19 during the acute phase or for those who had experienced long COVID. Moreover, being hospitalised in the acute phase was associated with additional utility decrements during both acute COVID-19 (&#x3b2;=-0.147, p&#x2009;=&#x2009;0.026) and long (&#x3b2;=-0.186, p&#x2009;&lt;&#x2009;0.001) COVID.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients perceived their HRQoL to have varied significantly over the course of a mild-to-moderate COVID-19 infection. However, HRQoL was found to return to pre-COVID-19 levels, even for patients who had been hospitalised for COVID-19 during the acute phase or for those who had experienced long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soare</LastName><ForeName>Ioana-Alexandra</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>PHMR Limited, Ashby Business Park, Nottingham Road, LE651NG, Ashby-De-La-Zouch, UK. alexandra.soare@putassoc.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Wajeeha</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendes</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pfizer Ltd, Tadworth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Waqas</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>PHMR Limited, Ashby Business Park, Nottingham Road, LE651NG, Ashby-De-La-Zouch, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Ltd, Tadworth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Amie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwell</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longworth</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>PHMR Limited, Ashby Business Park, Nottingham Road, LE651NG, Ashby-De-La-Zouch, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Frauke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>PHMR Limited, Ashby Business Park, Nottingham Road, LE651NG, Ashby-De-La-Zouch, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Qual Life Outcomes</MedlineTA><NlmUniqueID>101153626</NlmUniqueID><ISSNLinking>1477-7525</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EQ-5D-5L</Keyword><Keyword MajorTopicYN="N">Health-related quality of life (HRQoL)</Keyword></KeywordList><CoiStatement>The authors declare they have financial competing interests as specified at the end of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>29</Day><Hour>23</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38287294</ArticleId><ArticleId IdType="pmc">PMC10826014</ArticleId><ArticleId IdType="doi">10.1186/s12955-024-02230-5</ArticleId><ArticleId IdType="pii">10.1186/s12955-024-02230-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet Reg Health-Europe. 2021;6:100109. doi: 10.1016/j.lanepe.2021.100109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100109</ArticleId><ArticleId IdType="pmc">PMC8106239</ArticleId><ArticleId IdType="pubmed">33997835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine. 2020.</Citation></Reference><Reference><Citation>Johns Hopkins University. Coronavirus Resource Center 2022 [Available from: https://coronavirus.jhu.edu/.</Citation></Reference><Reference><Citation>Menni C, Valdes A, Freydin MB, Ganesh S, Moustafa JE-S, Visconti A et al. Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection. MedRxiv. 2020.</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus disease (COVID-19): similarities and differences with influenza 2020 [Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza#:~:text=For%20COVID%2D19%2&#xa0;C,observed%20for%20influenza%20infection.</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021:1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 September 2021 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2september2021.</Citation></Reference><Reference><Citation>Nandasena H, Pathirathna M, Atapattu A, Prasanga P. Quality of life of COVID 19 patients after discharge: systematic review. PLoS ONE. 2022;17(2):e0263941. doi: 10.1371/journal.pone.0263941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263941</ArticleId><ArticleId IdType="pmc">PMC8849513</ArticleId><ArticleId IdType="pubmed">35171956</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien K, Townsend L, Dowds J, Bannan C, Nadarajan P, Kent B, et al. 1-year quality of life and health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study. Respir Res. 2022;23(1):1&#x2013;11. doi: 10.1186/s12931-022-02032-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02032-7</ArticleId><ArticleId IdType="pmc">PMC9067558</ArticleId><ArticleId IdType="pubmed">35509060</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. New definitions for long COVID developed with patients and carers 2022 [.</Citation></Reference><Reference><Citation>Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ&#x2010;5 D&#x2010;5 L value set for E ngland. Health Econ. 2018;27(1):7&#x2013;22. doi: 10.1002/hec.3564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3564</ArticleId><ArticleId IdType="pmc">PMC6680214</ArticleId><ArticleId IdType="pubmed">28833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan SS, Wang M, Singh N, Jacob AP, Parker SA, Czap AL, et al. Retrospectively collected EQ-5D-5L data as valid proxies for imputing missing information in Longitudinal studies. Value in Health. 2021;24(12):1720&#x2013;7. doi: 10.1016/j.jval.2021.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2021.07.007</ArticleId><ArticleId IdType="pubmed">34838269</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hout B, Janssen M, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health. 2012;15(5):708&#x2013;15. doi: 10.1016/j.jval.2012.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2012.02.008</ArticleId><ArticleId IdType="pubmed">22867780</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. Guide to the Methods of Technology Appraisal 2013. 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">27905712</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene W. Econometric Analysis. New York University: Stern School of Business; 2018.</Citation></Reference><Reference><Citation>Raftery AE. Bayesian model selection in social research. Sociological methodology. 1995:111&#x2013;&#x2009;63.</Citation></Reference><Reference><Citation>Grimes DA, Schulz KF. Bias and causal associations in observational research. The Lancet. 2002;359(9302):248&#x2013;52. doi: 10.1016/S0140-6736(02)07451-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)07451-2</ArticleId><ArticleId IdType="pubmed">11812579</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Digital. Health Survey for England 2019 2020 [Available from: https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2019.</Citation></Reference><Reference><Citation>Sandmann FG, Tessier E, Lacy J, Kall M, Van Leeuwen E, Charlett A, et al. Long-term health-related quality of life in Non-hospitalized Coronavirus Disease 2019 (COVID-19) cases with confirmed severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in England: longitudinal analysis and cross-sectional comparison with controls. Clinical Infectious Diseases; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903473</ArticleId><ArticleId IdType="pubmed">35245941</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco M, Sun X, Moran MM, Coetzer H, Zamparo JM, Puzniak L et al. Impact of COVID-19 and Effects of Vaccination with BNT162b2 on Patient-Reported Health-Related Quality of Life, Symptoms, and Work Productivity Among US Adult Outpatients with SARS-CoV-2. medRxiv. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722994</ArticleId><ArticleId IdType="pubmed">36469198</ArticleId></ArticleIdList></Reference><Reference><Citation>Meys R, Delbressine JM, Go&#xeb;rtz YMJ, Vaes AW, Machado FVC, Van Herck M, et al. Generic and respiratory-specific quality of life in non-hospitalized patients with COVID-19. J Clin Med. 2020;9(12):3993. doi: 10.3390/jcm9123993.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9123993</ArticleId><ArticleId IdType="pmc">PMC7764406</ArticleId><ArticleId IdType="pubmed">33317214</ArticleId></ArticleIdList></Reference><Reference><Citation>Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev PharmacoEcon Outcomes Res. 2014;14(2):221&#x2013;33. doi: 10.1586/14737167.2014.894462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737167.2014.894462</ArticleId><ArticleId IdType="pubmed">24625040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkinson NS, Rossi N, El-Sayed Moustafa J, Laverty AA, Quint JK, Freidin M, et al. Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. Thorax. 2021;76(7):714&#x2013;22. doi: 10.1136/thoraxjnl-2020-216422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216422</ArticleId><ArticleId IdType="pubmed">33402392</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu G, Zhen Q, Wang W, Fan S, Wu Q, Zhang C, et al. Health-related quality of life of COVID&#x2010;19 patients after discharge: a multicenter follow&#x2010;up study. J Clin Nurs. 2021;30(11&#x2013;12):1742&#x2013;50. doi: 10.1111/jocn.15733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.15733</ArticleId><ArticleId IdType="pmc">PMC8013595</ArticleId><ArticleId IdType="pubmed">33656210</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England. NHS sets out long COVID action plan for thousands of people with persistent symptoms 2022 [Available from: https://www.england.nhs.uk/2022/07/nhs-sets-out-long-covid-action-plan-for-thousands-of-people-with-persistent-symptom/.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>